KCNJ2 and cardiovascular disorder: Our hypothesis that the inhibition of lipolysis in VAT from obese mice and human subjects prevents Kir2.1 impairment is based on the following lines of evidence: first, the release of FAs from VAT is a major contributor to insulin resistance and cardiovascular disease [7,12–14].